{
    "nct_id": "NCT05961839",
    "official_title": "A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "inclusion_criteria": "* ≥ 18 years of age.\n* Life expectancy ≥ 8 weeks.\n* Confirmed diagnosis of R/R AML or High Risk (HR) and Very High Risk (VHR) MDS.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active malignancies within two years prior to the first dose, or requiring ongoing treatment, not related to AML or MDS.\n* Clinical evidence of central nervous system (CNS) or pulmonary leukostasis, ≥ Grade 3 disseminated intravascular coagulation, or active CNS leukemia.\n* Use of experimental drug, or therapy, or anti-cancer therapy within 14 days or 5 half-lives of the first dose of study drug.\n* QT interval corrected for heart rate per Fridericia's formula ≥470 msec during screening ECG.",
    "miscellaneous_criteria": ""
}